Press-release for stocks for INCY listed in the nyse exchange

symbols : INCY exchanges : Nyse

save search

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -6.6% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K

Health Technology

| -4.76% | O: -0.23% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -6.71% | O: -0.07% H: 0.09% C: -0.7%
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| -16.36% | O: -0.66% H: 4.19% C: 3.13%
MOR | $17.96 -0.5% -0.5% 180K

Health Technology

| -0.66% | O: 0.22% H: 0.22% C: -0.93%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -10.97% | O: 0.03% H: 1.47% C: -0.72%
year update financial results

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -0.91% | O: -0.6% H: 0.45% C: 0.08%
MRUS | $39.83 -1.58% -1.61% 800K

Health Technology

| -15.71% | O: 2.3% H: 0.58% C: -2.69%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -11.94% | O: 0.38% H: 0.0% C: -3.07%
business year update financial results

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| -7.02% | O: -3.56% H: 2.91% C: -3.34%
MOR | $17.96 -0.5% -0.5% 180K

Health Technology

| 4.15% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $15.62 -2.8% -2.88% 1M

Health Technology

| -10.16% | O: -5.25% H: 2.94% C: 2.18%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
financial

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -1.6% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | $138.24 -4.19% 800

Health Technology

| 12.13% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | $9.47 -1.11% 520K

Manufacturing

| -13.68% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -7.41% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -7.44% | O: 0.7% H: 0.0% C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M

Health Technology

| -3.58% | O: 1.22% H: 0.07% C: -0.43%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 1.83% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -2.91% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| -4.57% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | News | $14.08 -0.99% -0.99% 470K

Health Technology

| -25.59% | O: -1.15% H: 1.03% C: -1.5%
VRTX | News | $394.43 0.24% 0.24% 1.3M

Health Technology

| -5.63% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -1.49% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K

Health Technology

| -8.91% | O: -3.1% H: 1.2% C: -0.8%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $194.39 2.03% 1.99% 1.6M

Health Technology

| -20.26% | O: -3.72% H: 0.58% C: -3.82%
AZN | $68.56 0.29% 0.29% 4.7M

Health Technology

| 11.16% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $360.11 0.47% 0.47% 330K

Health Technology

| -5.61% | O: -2.3% H: 1.65% C: 0.83%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -10.02% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -2.19% | O: 1.33% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -11.42% | O: -0.65% H: 0.57% C: -3.21%
first management drug application china

Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
Published: 2024-01-30 (Crawled : 14:00) - biospace.com/
A | $132.73 0.22% 0.0% 1.3M

Health Technology

| 2.99% | O: 0.0% H: 1.27% C: 1.09%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -12.65% | O: 0.05% H: 0.0% C: -2.02%
collaboration companion diagnostics advanced

Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K

| -6.94% | O: 0.2% H: 5.99% C: 5.65%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -8.89% | O: 0.8% H: 0.0% C: 0.0%
MTEM | $1.455 -2.02% -2.06% 13K

Health Technology

| -60.16% | O: -2.94% H: 3.03% C: 3.03%
IONS | $40.64 -0.42% -0.42% 850K

Health Technology

| -20.88% | O: 0.43% H: 0.27% C: -0.6%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -13.3% | O: 0.66% H: 0.64% C: -1.11%
IMAB | $1.81 0.56% 0.55% 340K

Health Technology

| -0.55% | O: 1.1% H: 0.27% C: -1.64%
companies growth market

CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K

| -1.53% | O: 1.59% H: 1.14% C: -1.42%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 19.23% | O: 0.61% H: 1.52% C: 0.03%
PSTX | News | $2.02 1.0% 0.99% 640K

Health Technology

| -35.89% | O: 1.57% H: 4.94% C: 1.54%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -14.63% | O: 0.29% H: 0.15% C: -1.95%
BEAM | $23.9 -1.69% -1.72% 4.5M

Health Technology

| 2.8% | O: 1.88% H: 0.88% C: -2.79%
t-cell therapy growth study market

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 19.93% | O: 0.65% H: 0.69% C: -0.73%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -11.68% | O: 0.74% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -19.75% | O: 0.0% H: 0.53% C: -2.19%
obesity first chinese key trial

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight
Published: 2024-01-08 (Crawled : 22:00) - prnewswire.com
INAB | $1.0 -4.76% -5.0% 280K

| -33.33% | O: 2.67% H: 13.64% C: 9.74%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -10.1% | O: 0.23% H: 0.0% C: 0.0%
MCRB | $0.5671 -2.93% -3.02% 3.7M

Health Technology

| -62.82% | O: 26.92% H: 3.54% C: -27.78%
DTIL | $9.75 -9.05% -9.95% 170K

Health Technology

| 2593.47% | O: 10.0% H: 14.23% C: 0.09%
OMER | $3.045 -5.14% -5.42% 390K

Health Technology

| -6.44% | O: -0.56% H: 13.38% C: 11.27%
MRKR | $4.25 3.65% 3.52% 15K

Consumer Services

| -12.75% | O: 1.21% H: 0.0% C: -0.8%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -19.75% | O: 0.0% H: 0.53% C: -2.19%
cell study market

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published: 2024-01-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.94% | O: -0.02% H: 0.41% C: 0.41%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 28.79% | O: -0.43% H: 2.12% C: 2.03%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -8.26% | O: -0.45% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -15.88% | O: -0.64% H: 4.97% C: 4.9%
ibi362 obesity first chinese study

Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.87% | O: 0.28% H: 0.0% C: -1.32%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 29.11% | O: 0.08% H: 0.81% C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.68% | O: 0.52% H: 0.72% C: -0.34%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -15.73% | O: 0.35% H: 1.07% C: -0.27%
candidate tumors collaboration trial advanced china therapy

THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR
Published: 2023-12-27 (Crawled : 15:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.51% | O: 0.36% H: 0.03% C: 0.03%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.45% | O: 0.39% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -6.57% | O: 1.2% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -15.56% | O: -0.18% H: 0.56% C: 0.38%
health year skin

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Published: 2023-12-18 (Crawled : 00:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 32.34% | O: 1.61% H: 1.14% C: 0.57%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.89% | O: 1.25% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -15.22% | O: -0.03% H: 0.06% C: -2.67%
ibi362 obesity publication communications chinese results

Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
Published: 2023-12-13 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.13% | O: -0.06% H: 2.36% C: 2.36%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 29.14% | O: 0.32% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.01% | O: -0.27% H: 2.28% C: 2.16%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -14.61% | O: 0.95% H: 3.83% C: 2.79%
tyvyt drug china

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.66% | O: -2.77% H: 0.49% C: 0.49%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 28.8% | O: 0.99% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -2.23% | O: -0.6% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -3.65% | O: -0.2% H: 1.7% C: 1.3%
rient-16 treatment results study

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight
Published: 2023-11-22 (Crawled : 22:00) - prnewswire.com
TGTX | News | $13.79 -1.43% -1.45% 3.7M

Health Technology

| Email alert Add to watchlist
NRIX | $13.6 -5.82% -6.18% 1M

Health Technology

| Email alert Add to watchlist
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| Email alert Add to watchlist
EPZM | $1.47 -1.34% 0.0%

Health Technology

| Email alert Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| Email alert Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| Email alert Add to watchlist
IOVA M | $11.32 -3.41% -3.53% 5.3M

Health Technology

| Email alert Add to watchlist
BPTH | News | $4.17 -0.71% -0.96% 2.1M

Health Technology

| Email alert Add to watchlist
RVMD S | $34.95 -2.46% -2.52% 1.2M

Health Technology

| Email alert Add to watchlist
IGMS | $7.2 -2.83% -2.92% 220K

Health Technology

| Email alert Add to watchlist
cell market

Key Market Analysis of Sickle Cell Disease, Fanconi Anemia, and Diamond-Blackfan Anemia in the Inherited Types of Anemia Therapeutic Space | Insights by DelveInsight
Published: 2023-11-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 0.16% | O: 0.13% H: 1.36% C: 0.38%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -1.78% | O: 1.88% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -2.19% | O: 0.13% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -3.45% | O: -2.76% H: 1.5% C: 0.06%
ALPN | $64.535 0.16% 0.16% 4M

Health Technology

| 359.52% | O: -0.21% H: 0.0% C: -3.79%
anemia cell space market

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 30.12% | O: 0.97% H: 0.0% C: 0.0%
MRUS | $39.83 -1.58% -1.61% 800K

Health Technology

| 87.1% | O: 3.51% H: 9.56% C: 9.56%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -2.13% | O: 0.52% H: 1.38% C: 1.11%
business update financial results

← Previous
1
2
3
4
5
6
7
8
9
…
13
14
Next →

symbols : INCY exchanges : Nyse

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

symbols : INCY exchanges : Nyse save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

symbols : INCY exchanges : Nyse

save search